As per reports, Pfizer (PFE) released Q3 earnings recently, reporting sales of $12.13B and EPS of 72 cents per share. The analysts were expecting EPS of 69 cents per share on $12.3 billion in sales.
The company narrowed its yearly earning guidance to $2.88-$2.93 a share on revenue of $48.8 billion to $49.5 billion from $2.85-$2.95 on revenue of $48.6 billion to $50.6 billion. The company reported lowered sales by about $500 million, caused by the pandemic, and also as more patients postpone or cancel doctor visits during the pandemic.
Pfizer and BioNTech are reported to be in the lead in the race for the release of a Covid-19 vaccine. Pfizer’s chief executive informed that the company is expecting to have final-phase clinical trial data by the third week of November. Pfizer has reportedly enrolled more than 42,000 participants in its Phase 2/3 clinical trials and plans to expand the trial to about 44,000 participants from 30,000, assuring that the trial includes more participants from diverse demographics.
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. To learn more about Pfizer and to track its progress please visit the Vista Partners Pfizer Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.